Cisplatin and S-1 for urachal carcinoma: A single-institution case series.

Abstract

INTRODUCTION:

Urachal carcinoma is a rare cancer, manifesting predominantly as adenocarcinoma, and could be treated with chemotherapy in patients with advanced or recurrent disease. However, any standard chemotherapy regimens are yet to be determined.

CASE PRESENTATION:

We retrospectively reviewed five patients with urachal adenocarcinoma treated with a potent first-line chemotherapy, cisplatin and S-1, between 2011 and 2014. Among the five patients, three were males. The median age at diagnosis was 61 years, ranging from 47 to 67. The most common symptom at their first visit was macroscopic hematuria. The best response was stable disease in four patients, which persisted for 7 months. Three patients experienced only one episode of grade 3 toxicity. Cisplatin and S-1 was well tolerated and safe.

CONCLUSION:

The activity of cisplatin and S-1 is modest and more efficacious treatment is desired against urachal carcinoma.

• Authors: Tetsuya Urasaki, Yoichi Naito, Nobuaki Matsubara, Masaoki Sasaki, Takahiro Kogawa, Ako Hosono
• Journal: IJU case reports (IJU Case Rep) Vol. 2 Issue 3 Pg. 150-154 (May 2019) ISSN: 2577-171X [Electronic] Australia
• PMID: 32743398 (Publication Type: Case Reports)
• Copyright: © 2019 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association.